Adoptive immunotherapy for cancer: harnessing the T cell response (original) (raw)

• Deguine, J., Breart, B., Lemaitre, F., Di Santo, J. P. & Bousso, P. Intravital imaging reveals distinct dynamics for natural killer and CD8+ T cells during tumor regression. Immunity 33, 632–644 (2010).
  Article CAS PubMed Google Scholar
• Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011). This study provides evidence that gene-engineered T cells can treat other solid tumour histologies (in this case, metastatic synovial cell sarcoma), in addition to melanoma.
  Article PubMed PubMed Central Google Scholar
• Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 8 Dec 2011 (doi:10.1182/blood-2011-10-384388). References 2, 3, 5 and 7 demonstrate the therapeutic power of genetically engineered T cells in the treatment of CD19+ lymphoma.
  Article CAS PubMed Google Scholar
• Baitsch, L. et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Offringa, R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21, 190–199 (2009).
  Article CAS PubMed Google Scholar
• Restifo, N. P. et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265–272 (1993).
  Article CAS PubMed Google Scholar
• Restifo, N. P. et al. Loss of functional β2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100–108 (1996).
  Article CAS PubMed Google Scholar
• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  Article CAS PubMed Google Scholar
• Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647 (1991).
  Article CAS PubMed Google Scholar
• Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).
  Article CAS PubMed Google Scholar
• Bos, R. et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68, 8446–8455 (2008).
  Article CAS PubMed Google Scholar
• Overwijk, W. W. & Restifo, N. P. Autoimmunity and the immunotherapy of cancer: targeting the “self” to destroy the “other”. Crit. Rev. Immunol. 20, 433–450 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Overwijk, W. W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277–286 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA 91, 3515–3519 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535–546 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, D. C. et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl Acad. Sci. USA 105, 8061–8066 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981–989 (2009).
  Article PubMed Google Scholar
• Davies, M. A. & Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29, 5545–5555 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Walia, V., Mu, E. W., Lin, J. C. & Samuels, Y. Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 25, 155–170 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gilchrest, B. A. Molecular aspects of tanning. J. Invest. Dermatol. 131, e14–e17 (2011).
  Article PubMed Google Scholar
• Robbins, P. F. et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185–1192 (1996).
  Article CAS PubMed Google Scholar
• Brenner, M. K. & Heslop, H. E. Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 22, 251–257 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838–1847 (2009).
  Article CAS PubMed Google Scholar
• Anders, K. et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 20, 755–767 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hofmann, O. et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105, 20422–20427 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Almeida, L. G. et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 37, D816–D819 (2009).
  Article CAS PubMed Google Scholar
• Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome — biological and translational implications. Nature Rev. Cancer 11, 726–734 (2011).
  Article CAS Google Scholar
• Guo, Z. S. et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 66, 1105–1113 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wargo, J. A. et al. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58, 383–394 (2009).
  Article CAS PubMed Google Scholar
• Simpson, A. J., Caballero, O. L., Jungbluth, A., Chen, Y. T. & Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nature Rev. Cancer 5, 615–625 (2005).
  Article CAS Google Scholar
• Chinnasamy, N. et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186, 685–696 (2011).
  Article CAS PubMed Google Scholar
• Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA 8 Aug 2011 (doi:10.1073/pnas.1104303108).
  Article Google Scholar
• Engels, B., Rowley, D. A. & Schreiber, H. Targeting stroma to treat cancers. Semin. Cancer Biol. 22, 41–49 (2012).
  Article CAS PubMed Google Scholar
• Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330, 827–830 (2010).
  Article CAS PubMed Google Scholar
• Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953–3968 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171–6180 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Rev. Cancer 10, 505–514 (2010).
  Article CAS Google Scholar
• Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 29, 2177–2183 (1969).
  CAS PubMed Google Scholar
• Greenberg, P. D., Cheever, M. A. & Fefer, A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2− lymphocytes. J. Exp. Med. 154, 952–963 (1981). An important and remarkable landmark paper that describes in significant detail the scientific foundations of lymphodepletion prior to adoptive immunotherapy using what are now known as CD4+ T cells.
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. & Terry, W. D. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25, 323–388 (1977).
  Article CAS PubMed Google Scholar
• Wang, M. et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154, 4685–4692 (1995).
  CAS PubMed Google Scholar
• Palmer, D. C. et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173, 7209–7216 (2004).
  Article CAS PubMed Google Scholar
• Chen, P. W. et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 224–231 (1996).
  CAS PubMed Google Scholar
• Bronte, V. et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154, 5282–5292 (1995).
  CAS PubMed Google Scholar
• Cormier, J. N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3, 37–44 (1997).
  CAS PubMed PubMed Central Google Scholar
• Leitner, W. W. et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature Med. 9, 33–39 (2003).
  Article CAS PubMed Google Scholar
• Ying, H. et al. Cancer therapy using a self-replicating RNA vaccine. Nature Med. 5, 823–827 (1999).
  Article CAS PubMed Google Scholar
• Overwijk, W. W. et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982–2987 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169–6176 (2005).
  Article CAS PubMed Google Scholar
• Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595–1601 (1997).
  Article CAS PubMed Google Scholar
• Rao, J. B. et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7–1 expression. J. Immunol. 156, 3357–3365 (1996).
  CAS PubMed Google Scholar
• Irvine, K. R. et al. Recombinant virus vaccination against “self” antigens using anchor-fixed immunogens. Cancer Res. 59, 2536–2540 (1999).
  CAS PubMed PubMed Central Google Scholar
• Irvine, K. R., Rao, J. B., Rosenberg, S. A. & Restifo, N. P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156, 238–245 (1996).
  CAS PubMed Google Scholar
• Carroll, M. W. et al. Construction and characterization of a triple-recombinant vaccinia virus encoding B7–1, interleukin 12, and a model tumor antigen. J. Natl Cancer Inst. 90, 1881–1887 (1998).
  Article CAS PubMed Google Scholar
• Schlom, J. Recent advances in therapeutic cancer vaccines. Cancer Biother. Radiopharm. 27, 2–5 (2012).
  Article PubMed PubMed Central Google Scholar
• Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915 (2004).
  Article CAS PubMed Google Scholar
• Klebanoff, C. A., Acquavella, N., Yu, Z. & Restifo, N. P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239, 27–44 (2011). An update on recent vaccine trials showing that although current therapeutic cancer vaccines can extend survival in some studies (by months, not years), they are rarely if ever curative.
  Article CAS PubMed PubMed Central Google Scholar
• Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010). Although criticized by some for the trial design, this study nevertheless served as a key basis for the FDA licensing of sipuleucel-T (Provenge; Dendreon).
  Article CAS PubMed Google Scholar
• Itzhaki, O. et al. Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34, 212–220 (2011).
  Article PubMed Google Scholar
• Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646–2655 (2010).
  Article CAS PubMed Google Scholar
• Klebanoff, C. A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343–5352 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nature Immunol. 3, 999–1005 (2002).
  Article CAS Google Scholar
• Ogino, S., Galon, J., Fuchs, C. S. & Dranoff, G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nature Rev. Clin. Oncol. 8, 711–719 (2011).
  Article CAS Google Scholar
• Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011).
  Article CAS PubMed Google Scholar
• Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kerkar, S. P. et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 34, 343–352 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Abad, J. D. et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1–6 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Med. 14, 1264–1270 (2008).
  Article CAS PubMed Google Scholar
• Recombinant DNA Advisory Committee. Human gene transfer protocols. National Institutes of Health [online], (2011).
• Varela-Rohena, A. et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Med. 14, 1390–1395 (2008).
  Article CAS PubMed Google Scholar
• Sadelain, M., Brentjens, R. & Riviere, I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215–223 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Baeuerle, P. A. & Itin, C. Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. Curr. Pharm. Biotechnol. 14 Feb 2012 [epub ahead of print].
• Choi, B. D. et al. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin. Biol. Ther. 11, 843–853 (2011).
  Article CAS PubMed Google Scholar
• Merhavi-Shoham, E., Haga-Friedman, A. & Cohen, C. J. Genetically modulating T-cell function to target cancer. Semin. Cancer Biol. 22, 14–22 (2011).
  Article CAS PubMed Google Scholar
• Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nature Med. 17, 1290–1297 (2011).
  Article CAS PubMed Google Scholar
• Stephan, M. T. et al. T cell-encoded CD80 and 4–1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Med. 13, 1440–1449 (2007).
  Article CAS PubMed Google Scholar
• Charo, J. et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65, 2001–2008 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 21 Feb 2012 (doi:10.1182/blood-2011-12-400044).
  Article CAS PubMed PubMed Central Google Scholar
• Kerkar, S. P. et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746–4757 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kerkar, S. P. et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725–6734 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Peng, W. et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16, 5458–5468 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Med. 16, 565–570 (2010). An important paper that explores in significant detail the consequences of 'mispairing' of transduced TCR α- and β-chains.
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18, 1744–1745 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Vatakis, D. N. et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl Acad. Sci. USA 108, e1408–e1416 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ha, S. P. et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J. Clin. Invest. 120, 4273–4288 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jorritsma, A., Schotte, R., Coccoris, M., de Witte, M. A. & Schumacher, T. N. Prospects and limitations of T cell receptor gene therapy. Curr. Gene Ther. 11, 276–287 (2011).
  Article CAS PubMed Google Scholar
• Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. & Sadelain, M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666–668 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011). This paper describes a highly effective means of rapidly deleting gene-engineered T cells in the event of toxicity.
  Article CAS PubMed PubMed Central Google Scholar
• North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063–1074 (1982).
  Article CAS PubMed Google Scholar
• Cheever, M. A., Greenberg, P. D. & Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 125, 711–714 (1980).
  CAS PubMed Google Scholar
• Bronte, V. et al. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood 96, 3838–3846 (2000).
  CAS PubMed Google Scholar
• Wrzesinski, C. et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117, 492–501 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Wrzesinski, C. et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1–7 (2010).
  Article PubMed PubMed Central Google Scholar
• Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233–5239 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nature Rev. Immunol. 12, 253–268 (2012).
  Article CAS Google Scholar
• Bronte, V. et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161, 5313–5320 (1998). One of the first descriptions of the suppressive myeloid subset later known as MDSCs.
  CAS PubMed Google Scholar
• Seung, L. P., Rowley, D. A., Dubey, P. & Schreiber, H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl Acad. Sci. USA 92, 6254–6258 (1995). This paper describes a classic experiment demonstrating that depletion of GR1+ cells can enhance tumour immunotherapy.
  Article CAS PubMed PubMed Central Google Scholar
• Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907–912 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Paulos, C. M. et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197–2204 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Antony, P. A. et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591–2601 (2005).
  Article CAS PubMed Google Scholar
• Kastenmuller, W. et al. Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J. Immunol. 187, 3186–3197 (2011).
  Article CAS PubMed Google Scholar
• Antony, P. A. & Restifo, N. P. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28, 120–128 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Bluestone, J. A. The yin and yang of interleukin-2-mediated immunotherapy. N. Engl. J. Med. 365, 2129–2131 (2011).
  Article PubMed Google Scholar
• Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616–1626 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Gattinoni, L., Powell, D. J. Jr, Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nature Rev. Immunol. 6, 383–393 (2006).
  Article CAS Google Scholar
• Sallusto, F. & Lanzavecchia, A. Memory in disguise. Nature Med. 17, 1182–1183 (2011).
  Article CAS PubMed Google Scholar
• Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214–224 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, D. C. & Restifo, N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 30, 592–602 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hinrichs, C. S. et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl Acad. Sci. USA 106, 17469–17474 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hinrichs, C. S. et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808–814 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Klebanoff, C. A. et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571–9576 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101, 1969–1974 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294–305 (2008). An important study in non-human primates showing that cells derived from central memory T cells are more persistentthan those derived from effector memory T cells.
  Article CAS PubMed Google Scholar
• Wang, X. et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117, 1888–1898 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Chapuis, A. et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. 5 Mar 2012 (doi:10.1073/pnas.1113748109). References 122 and 126 show that central memory T cells mediate superior antitumour immunity compared with effector memory T cells in murine systems.
  Article CAS Google Scholar
• Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S. G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nature Med. 11, 1299–1305 (2005).
  Article CAS PubMed Google Scholar
• Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Med. 15, 808–813 (2009).
  Article CAS PubMed Google Scholar
• Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nature Rev. Immunol. 11, 330–342 (2011).
  Article CAS Google Scholar
• June, C. H., Bluestone, J. A., Nadler, L. M. & Thompson, C. B. The B7 and CD28 receptor families. Immunol. Today 15, 321–331 (1994).
  Article CAS PubMed Google Scholar
• Ji, Y. et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunol. 12, 1230–1237 (2011).
  Article CAS Google Scholar
• Hinrichs, C. S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326–5333 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, H. et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71, 3516–3527 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Gattinoni, L., Ji, Y. & Restifo, N. P. Wnt/β-catenin signaling in T-cell immunity and cancer immunotherapy. Clin. Cancer Res. 16, 4695–4701 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci. Transl. Med. 1, 11ps12 (2009).
  Article PubMed PubMed Central Google Scholar
• Pardoll, D. M. & Topalian, S. L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588–594 (1998).
  Article CAS PubMed Google Scholar
• Xie, Y. et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651–667 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl Acad. Sci. USA 96, 8633–8638 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Corthay, A. et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371–383 (2005).
  Article CAS PubMed Google Scholar
• Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Muranski, P. et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35, 972–985 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Frankel, T. L. et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 184, 5988–5998 (2010).
  Article CAS PubMed Google Scholar
• Yee, C. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 16, 367–373 (2010).
  Article CAS PubMed Google Scholar
• Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Nakayamada, S., Takahashi, H., Kanno, Y. & O'Shea, J. J. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 15 Feb 2012 (doi:10.1016/j.coi.2012.01.014).
  Article CAS PubMed PubMed Central Google Scholar
• Nishimura, T. et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46, S52–S61 (2000).
  Article CAS PubMed Google Scholar
• Muranski, P. & Restifo, N. P. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21, 200–208 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zou, W. & Restifo, N. P. TH17 cells in tumour immunity and immunotherapy. Nature Rev. Immunol. 10, 248–256 (2010).
  Article CAS Google Scholar
• Muranski, P. & Restifo, N. P. Does IL-17 promote tumor growth? Blood 114, 231–232 (2009).
  Article CAS PubMed Google Scholar
• Hinrichs, C. S. et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596–599 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183, 7161–7168 (2009).
  Article CAS PubMed Google Scholar
• Boni, A. et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 112, 4746–4754 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Restifo, N. P. & Bachinski, M. Imagining a cure: for cancer patients, close is not good enough. The Scientist April 2011, 28–29 (2011).
• Blank, C. U., Hooijkaas, A. I., Haanen, J. B. & Schumacher, T. N. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol. Immunother. 60, 1359–1371 (2011).
  Article PubMed Google Scholar
• Klebanoff, C. A. et al. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood 114, 1776–1783 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569–580 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Restifo, N. P. Can antitumor immunity help to explain “oncogene addiction”? Cancer Cell 18, 403–405 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rakhra, K. et al. CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485–498 (2010). A paper that explores the immunological consequences of oncogene withdrawal.
  Article CAS PubMed PubMed Central Google Scholar
• Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651–1656 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
  Article CAS PubMed Google Scholar
• DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405–409 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178–1183 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Kryczek, I. et al. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3, 104ra100 (2011).
  Article CAS PubMed PubMed Central Google Scholar